Pieris Pharmaceuticals, Inc. CEO Stephen S. Yoder to Be Interviewed on “The Big Biz Show” on September 23rd at 3:50 pm EDT

NEW YORK, NY, Sep 23, 2015 – Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a biotechnology company advancing novel bio-therapeutics through its proprietary Anticalin® technology platform, announced today that Chief Executive Officer, Stephen S. Yoder, will be interviewed today on “The Big Biz Show” hosted by Bob “Sully” Sullivan, airing Wednesday, September 23rd at 3:50 pm EDT.


In this exclusive interview, Mr. Yoder will discuss recent Company news as well as the plan to advance the Company’s patented and proprietary Anticalin technology to create differentiated drugs that could help patients suffering from cancer, severe asthma, anemia and other medical conditions with a high unmet medical need.


Date: Wednesday, September 23, 2015
Start Time: 3:50pm ET | 12:50pm PT | 2:50pm CT (U.S.)
Network: Syndicated: AFN, TiVo, CBS Radio, Fox Business, AOL, YouTube, Biz Talk Radio, Clear Channel
Show: The Big Biz Show
Host: Bob “Sully” Sullivan
TV Streamhttp://www.ustream.tv/biztv


About the Big Biz Show
The Big Biz Show is a nationally syndicated radio / television program broadcast on 150 stations throughout the country with a weekly reach of 1.7 million listeners reaching over 70 million homes. The Emmy Award winning show was named by TALKERS Magazine as one of the “Top 10 Most Influential Financial Shows” in the country is highly recognized for discussing current business events, internet related issues, and other hot topics in the business world; doing so in an informing, laid back, and humorous manner. Hosts, Bob “Sully” Sullivan and Russ “T Nailz” Stolnack; both are renowned and experienced radio broadcast personalities. The Big Biz Show airs Tuesday through Friday, 12:00 p.m. to 1:00 p.m. PT.


About Stephen S. Yoder
Stephen S. Yoder has been the President and CEO Pieris Pharmaceuticals since 2010. Prior to joining Pieris, from 2003 to 2010, he led the intellectual property and legal departments as General Counsel at MorphoSys AG, a biotechnology company involved in the development and research of antibodies. Mr. Yoder holds degrees in molecular biology and Spanish from Grove City College and a Juris Doctorate, with honors, from The George Washington University Law School.


About Pieris Pharmaceuticals, Inc.
Pieris is a clinical-stage biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan. Anticalin®, Anticalins® are registered trademarks of Pieris. For more information visit www.pieris.com.


A CommPro Worldwide PR Event




PR & Media Contact:

Matt Bird, CEO
CommPro Worldwide

C: +1 (646) 401-4499
E: matt.bird@commpro.com

Steve Sura
No Comments

Sorry, the comment form is closed at this time.